A melanocortin-receptor agonist, FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Studied for arousal via central nervous-system pathways rather than the vascular route.
Mechanism under study
Activates melanocortin receptors (notably MC4R) in the central nervous system, influencing sexual-arousal signaling upstream of the vascular mechanisms targeted by PDE5 inhibitors.
Research-reported dosing
Its approved regimen is 1.75 mg subcutaneously as needed before anticipated activity, with a per-day and per-month cap. Nausea is a common labeled effect.
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
A 1.75 mg dose ≈ 35 units (50 mcg per unit).
Open this mix in the calculator →Source research-grade PT-141 ↗Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
PT-141 FAQ
What is PT-141?
A melanocortin-receptor agonist, FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Studied for arousal via central nervous-system pathways rather than the vascular route.
What is the half-life of PT-141?
Approximately 2.7 hours (clinical).
What is the research-reported dosing for PT-141?
Its approved regimen is 1.75 mg subcutaneously as needed before anticipated activity, with a per-day and per-month cap. Nausea is a common labeled effect.
How is PT-141 reconstituted?
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
Is PT-141 FDA-approved?
PT-141 has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.